Worth Watching: NovaBay Pharmaceuticals, Inc. Can’t Burn Your Long Portfolio. Has Another Strong Session

Worth Watching: NovaBay Pharmaceuticals, Inc. Can't Burn Your Long Portfolio. Has Another Strong Session

The stock of NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) is a huge mover today! About 187,835 shares traded hands or 191.46% up from the average. NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) has risen 78.26% since February 29, 2016 and is uptrending. It has outperformed by 66.04% the S&P500.
The move comes after 8 months positive chart setup for the $45.78M company. It was reported on Oct, 3 by Barchart.com. We have $6.51 PT which if reached, will make NYSEMKT:NBY worth $30.67M more.

Analysts await NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) to report earnings on November, 15.

According to Zacks Investment Research, “NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of antimicrobial compounds, which it has named Aganocide compounds, which are based upon small molecules that are generated by white blood cells that defend the body against invading pathogens. NovaBay believes that Aganocide compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial and viral infections, including Methicillin-Resistant Staphylococcus aureus.”

More notable recent NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) news were published by: Marketwatch.com which released: “NovaBay Pharmaceuticals Inc.” on July 16, 2010, also Quotes.Wsj.com with their article: “News NovaBay Pharmaceuticals Inc.NBY” published on February 11, 2011, Businesswire.com published: “NovaBay Pharmaceuticals’ Neutrox ® Product Line Receives CE Mark and ISO …” on September 12, 2016. More interesting news about NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) were released by: Seekingalpha.com and their article: “NovaBay pulls in $7M from exercise of warrants” published on October 03, 2016 as well as Businesswire.com‘s news article titled: “NovaBay Pharmaceuticals Reports 2016 Second Quarter Financial Results” with publication date: August 11, 2016.

NBY Company Profile

NovaBay Pharmaceuticals, Inc., formerly NovaCal Pharmaceuticals, Inc., incorporated on April 19, 2010, is a biopharmaceutical company, which develops products for the eye care market. The Firm focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox. The Company’s Avenova with Neutrox removes debris from the skin on the eyelids and lashes without burning or stinging.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment